Skip to Main Content
Contribute Try STAT+ Today

Cancer patients inherit brand-new immune systems after undergoing bone marrow transplants. Though this intensive therapy can rid the body of malignancies, it often triggers graft-versus-host disease — a condition in which freshly adopted immune cells mount violent attacks on a person’s tissues and organs, viewing them as foreign.

Other than steroids, which only work about half of the time, there have been few options to treat the disease. GVHD, as the condition is known, is often fatal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.